Transformation of excess mortality in people with schizophrenia and bipolar disorder in Taiwan

Psychological Medicine

Volumn 47, Issue 14, 2017, Pages 2483-2493

  Pan, Y J ^a,b   Yeh, L L ^c   Chan, H Y ^d,e   Chang, C K ^f  

^a FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c ASIA UNIVERSITY   (Taiwan)

^d Taoyuan Psychiatric Center   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^f KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Bipolar disorder; excess mortality; schizophrenia; standardized mortality ratio

Indexed keywords

NEUROLEPTIC AGENT;

ADOLESCENT; ADULT; AGED; BIPOLAR DISORDER; COHORT ANALYSIS; EPIDEMIOLOGY; FEMALE; HUMAN; MALE; MIDDLE AGED; MORTALITY; SCHIZOPHRENIA; TAIWAN; TRENDS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; MORTALITY; SCHIZOPHRENIA; TAIWAN; YOUNG ADULT;

EID: 85018356330     PISSN: 00332917     EISSN: 14698978     Source Type: Journal    
DOI: 10.1017/S0033291717001040     Document Type: Article

References (45)

1. American Psychiatric Association (2002). Practice guideline for the treatment of patients with bipolar disorder (revision)-Introduction. American Journal of Psychiatry 159, 2-50.
2. Alexander GC, Gallagher SA, Mascola A, Moloney RM, Stafford RS (2011). Increasing off-label use of antipsychotic medications in the United States, 1995-2008. Pharmacoepidemiology and Drug Safety 20, 177-184.
3. Bardgett ME, Franks-Henry JM, Colemire KR, Juneau KR, Stevens RM, Marczinski CA, Griffith MS (2013). Adult rats treated with risperidone during development are hyperactive. Experimental and Clinical Psychopharmacology 21, 259-267.
4. Chang CK, Hayes RD, Broadbent M, Fernandes AC, Lee W, Hotopf M, Stewart R (2010). All-cause mortality among people with serious mental illness (SMI), substance use disorders, and depressive disorders in southeast London: a cohort study. BMC Psychiatry 10, 77.
5. Chen EY, Tang JY, Hui CL, Chiu CP, Lam MM, Law CW, Yew CW, Wong GH, ChungDW, Tso S, Chan KP, Yip KC, Hung SF, Honer WG (2011). Three-year outcome of phase-specific early intervention for first-episode psychosis: a cohort study in Hong Kong. Early Intervention in Psychiatry 5, 315-323.
6. Choi YK, Moran-Gates T, Gardner MP, Tarazi FI (2010). Effects of repeated risperidone exposure on serotonin receptor subtypes in developing rats. European Neuropsychopharmacology 20, 187-194.
7. Correll CU, Blader JC (2015). Antipsychotic use in youth without psychosis: a double-edged sword. JAMA Psychiatry 72, 859-860.
8. Correll CU, Joffe BI, Rosen LM, Sullivan TB, Joffe RT (2015). Cardiovascular and cerebrovascular risk factors and events associated with second-generation antipsychotic compared to antidepressant use in a non-elderly adult sample: results from a claims-based inception cohort study. World Psychiatry 14, 56-63.
9. Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK (2009). Cardiometabolic risk of secondgeneration antipsychotic medications during first-time use in children and adolescents. JAMA 302, 1765-1773.
10. Dutta R, Murray RM, Allardyce J, Jones PB, Boydell JE (2012). Mortality in first-contact psychosis patients in the U. K.: a cohort study. Psychological Medicine 42, 1649-1661.
11. Gardner-Sood P, Lally J, Smith S, Atakan Z, Ismail K, Greenwood KE, Keen A, O'Brien C, Onagbesan O, Fung C, Papanastasiou E, Eberhard J, Patel A, Ohlsen R, Stahl D, David A, Hopkins D, Murray RM, Gaughran F, IMPaCT team (2015). Cardiovascular risk factors and metabolic syndrome in people with established psychotic illnesses: baseline data from the IMPaCT randomized controlled trial. Psychological Medicine 45, 2619-2629.
12. Harris MG, Burgess PM, Chant DC, Pirkis JE, McGorry PD (2008). Impact of a specialized early psychosis treatment programme on suicide. Retrospective cohort study. Early Intervention in Psychiatry 2, 11-21.
13. Hayes RD, Downs J, Chang CK, Jackson RG, Shetty H, Broadbent M, Hotopf M, Stewart R (2015). The effect of clozapine on premature mortality: an assessment of clinical monitoring and other potential confounders. Schizophrenia Bulletin 41, 644-655.
14. Hennekens CH, Hennekens AR, Hollar D, Casey DE (2005). Schizophrenia and increased risks of cardiovascular disease. American Heart Journal 150, 1115-1121.
15. Higham J, Flowers J, Hall P (2005). Standardisation. Eastern Region Public Health Observatory: Cambridge. Issue 6 (http://www. scotpho. org. uk/downloads/methodology/INPHORM%206-FINAL. pdf).
16. Hoang U, Stewart R, Goldacre MJ (2011). Mortality after hospital discharge for people with schizophrenia or bipolar disorder: retrospective study of linked English hospital episode statistics, 1999-2006. BMJ 343, d5422.
17. Lahti M, Tiihonen J, Wildgust H, Beary M, Hodgson R, Kajantie E, Osmond C, Raikkonen K, Eriksson J (2012). Cardiovascular morbidity, mortality and pharmacotherapy in patients with schizophrenia. Psychological Medicine 42, 2275-2285.
18. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT (2002). The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288, 2709-2716.
19. Laursen TM, Mortensen PB, MacCabe JH, Cohen D, Gasse C (2014). Cardiovascular drug use and mortality in patients with schizophrenia or bipolar disorder: a Danish population-based study. Psychological Medicine 44, 1625-1637.
20. Lee T, Yang C, Wang T (2011). Population ageing and national health insurance expenditures: a time-to-death analysis. (in Chinese). Journal of Population Studies 43, 1-35.
21. Maher AR, Maglione M, Bagley S, Suttorp M, Hu JH, Ewing B, Wang Z, Timmer M, Sultzer D, Shekelle PG (2011). Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. JAMA 306, 1359-1369.
22. Mandell DJ, Unis A, Sackett GP (2011). Post-drug consequences of chronic atypical antipsychotic drug administration on the ability to adjust behavior based on feedback in young monkeys. Psychopharmacology (Berl) 215, 345-352.
23. Miller CJ, Li M, Penfold RB, Lee AF, Smith EG, Osser DN, Bajor L, Bauer MS (2014). Patterns of initiation of second generation antipsychotics for bipolar disorder: a month-by-month analysis of provider behavior. BMC Psychiatry 14, 339.
24. Ministry of Health and Welfare (2016). Cause of Death Statistics. Ministry of Health and Welfare: Taipei, Taiwan. (http://www. mohw. gov. Tw/CHT/DOS/Statistic. aspx? f-list-no=474&fod-list-no=3443).
25. Mitchell PB (2012). Bipolar disorder: the shift to overdiagnosis. Canadian Journal of Psychiatry 57, 659-665.
26. Morgan VA, McGrath JJ, Jablensky A, Badcock JC, Waterreus A, Bush R, Carr V, Castle D, CohenM, Galletly C, Harvey C, Hocking B, McGorry P, Neil AL, Saw S, Shah S, Stain HJ, Mackinnon A (2014). Psychosis prevalence and physical, metabolic and cognitive co-morbidity: data from the second Australian national survey of psychosis. Psychological Medicine 44, 2163-2176.
27. National Health Insurance Administration (2004). National Health Insurance Annual Statistical Report. Bureau of National Health Insurance: Taipei, Taiwan. (https://www. nhi. gov. Tw/Resource/webdata/20512-1-Attach-8661-1-s92. pdf).
28. National Health Insurance Administration (2011). The Report of Enrollment of National Health Insurance and Medical Health care Utilization of Alliens and Mainlanders. Bureau of National Health Insurance: Taipei, Taiwan. (http://www. nhi. gov. Tw/Resource/webdata/19485-4-194%E5%9F%B7%E8%A1%8C %E5%A0%B1%E5%91%8A6%E6%9C%88%20(%E9%99% 84%E9%8C%84%E4%BA%8C%E4%B9%8B%E9%99%84% E8%A1%A8). pdf).
29. National Health Insurance Administration (2017). Enrollment and Underwriting. Bureau of National Health Insurance: Taipei, Taiwan. (https://www. nhi. gov. Tw/Resource/webdata/20517-2-201702-National%20Health% 20Insurance%201. pdf).
30. National Institute for Health and Care Excellence (NICE) (2006). Bipolar Disorder: The Management of Bipolar Disorder in Adults, Children and Adolescents in Primary and Secondary Care. National Collaborating Centre for Mental Health: London, UK.
31. Olfson M, King M, Schoenbaum M (2015). Treatment of young people with antipsychotic medications in the United States. JAMA Psychiatry 72, 867-874.
32. Pan Y, Yeh L, Chen Y, Chan H (2016a). Three-year mortality in relation to early hospitalization and number of outpatient clinic visits in people with newly diagnosed bipolar disorder. General Hospital Psychiatry 43, 32-37.
33. Pan Y, Yeh L, Chen Y, Kuo K, Chang C (2016b). Hospital treatment, mortality and healthcare costs in relation to socioeconomic status among people with bipolar affective disorder. British Journal of Psychiatry Open 2, 10-17.
34. Reininghaus U, Dutta R, Dazzan P, Doody GA, Fearon P, Lappin J, Heslin M, Onyejiaka A, Donoghue K, Lomas B, Kirkbride JB, Murray RM, Croudace T, Morgan C, Jones PB (2015). Mortality in schizophrenia and other psychoses: a 10-year follow-up of the æSOP first-episode cohort. Schizophrenia Bulletin 41, 664-673.
35. Remington G (2006). Schizophrenia, antipsychotics, and the metabolic syndrome: is there a silver lining? American Journal of Psychiatry 163, 1132-1134.
36. Saha S, Chant D, McGrath J (2007). A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Archives of General Psychiatry 64, 1123-1131.
37. Taiwan's Ministry of the Interior (2017). Resident Population by 5-Year and 10-Year Age Group, 1990-2017. Taiwan's Ministry of the Interior: Taipei, Taiwan. (http://sowf. moi. gov. Tw/stat/month/m1-06. xls).
38. Tarricone I, Ferrari Gozzi B, Serretti A, Grieco D, Berardi D (2010). Weight gain in antipsychotic-naive patients: a review and meta-analysis. Psychological Medicine 40, 187-200.
39. Tiihonen J, Lonnqvist J, Wahlbeck K, Klaukka T, Niskanen L, Tanskanen A, Haukka J (2009). 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 374, 620-627.
40. Wahlbeck K, Westman J, Nordentoft M, Gissler M, Laursen TM (2011). Outcomes of Nordic mental health systems: life expectancy of patients with mental disorders. British Journal of Psychiatry 199, 453-458.
41. World Economic Outlook (WEO) data, IMF (2017). Implied PPP (Purchasing Power Parity) Conversion Rate. ECONSTATS: New York, USA. (http://www. econstats. com/weo/V013. htm).
42. Wu CS, Tsai YT, Tsai HJ (2015). Antipsychotic drugs and the risk of ventricular arrhythmia and/or sudden cardiac death: a nation-wide case-crossover study. Journal of the American Heart Association 4, e001568.
43. Wu CY, Chang CK, Hayes RD, Broadbent M, Hotopf M, Stewart R (2012a). Clinical risk assessment rating and all-cause mortality in secondary mental healthcare: the South London and Maudsley NHS Foundation Trust Biomedical Research Centre (SLAM BRC) Case Register. Psychological Medicine 42, 1581-1590.
44. Wu CY, Chen YJ, Ho HJ, Hsu YC, Kuo KN, Wu MS, Lin JT (2012b). Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection. JAMA 308, 1906-1914.
45. Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Beaulieu S, Alda M, O'Donovan C, Macqueen G, McIntyre RS, Sharma V, Ravindran A, Young LT, Milev R, Bond DJ, Frey BN, Goldstein BI, Lafer B, Birmaher B, Ha K, Nolen WA, Berk M (2013). Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disorders 15, 1-44.